Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Murray, Samuel ^a,e   Karavasilis, Vasilios ^b   Bobos, Mattheos ^b   Razis, Evangelia ^c   Papadopoulos, Savvas ^c   Christodoulou, Christos ^d   Kosmidis, Paris ^c   Fountzilas, George ^b  

^a BioMarker Solutions   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c HYGEIA HOSPITAL   (Greece)

^d METROPOLITAN HOSPITAL   (Greece)

^e Metropolitan Hospital ^*  (Greece)

Author keywords

EGFR; Erlotinib; Gefitinib; Predictive; Response; Somatic mutation

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; POLYSOME; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866292562     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-77     Document Type: Article

References (36)

1. Cancer statistics, 2009. Jemal A, Siegel R, Ward E, et al. CA Cancer J Clin 2009 59 225 249 10.3322/caac.20006 19474385
2. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. Schiller JH, Harrington D, Belani CP, et al. N Engl J Med 2002 346 92 98 10.1056/NEJMoa011954 11784875 (Pubitemid 34438899)
3. Epidermal growth factor receptor: a promising target in solid tumours. Laskin JJ, Sandler AB, Cancer Treat Rev 2004 30 1 17 10.1016/j.ctrv.2003.10.002 14766123 (Pubitemid 38240085)
4. EGFR antagonists in cancer treatment. Ciardiello F, Tortora G, N Engl J Med 2008 358 1160 1174 10.1056/NEJMra0707704 18337605 (Pubitemid 351398490)
5. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. Eur Respir J 2002 20 975 981 10.1183/09031936.02.00296502 12412692 (Pubitemid 35175137)
6. Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations? Hirsch FR, Bunn PA Jr, J Clin Oncol 2005 23 36 9044 9047 10.1200/JCO.2005.03.6129 16301593
7. Targeted therapies for non-small cell lung cancer: an evolving landscape. Pal SK, Figlin RA, Reckamp K, Mol Cancer Ther 2010 9 1931 1944 10.1158/1535-7163.MCT-10-0239 20571071
8. Erlotinib in lung cancer. Takano T, Ohe Y, N Engl J Med 2005 353 1739 1741 author reply 1739-1741 16240472
9. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. Science 2004 304 1497 1500 10.1126/science.1099314 15118125 (Pubitemid 38720929)
10. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Sordella R, Bell DW, Haber DA, Settleman J, Science 2004 305 1163 1167 10.1126/science.1101637 15284455 (Pubitemid 39100331)
11. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. N Engl J Med 2004 350 2129 2139 10.1056/NEJMoa040938 15118073 (Pubitemid 38637993)
12. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S, Nature Reviews Clinical Oncology 2009 6 352 366 10.1038/nrclinonc.2009.62 19483740
13. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. Mok TS, Wu YL, Thongprasert S, et al. N Engl J Med 2009 361 947 957 10.1056/ NEJMoa0810699 19692680
14. Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Dahabreh IJ, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S, Clin Cancer Res 2010 16 291 303 10.1158/1078-0432.CCR-09-1660 20028749
15. EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer. Dahabreh IJ, Linardou H, Kosmidis P, Bafaloukos D, Murray S, Ann Oncol 2011 22 545 552 10.1093/annonc/mdq432 20826716
16. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. Sasaki H, et al. J Cancer Res Clin Oncol 2008 134 569 577 10.1007/s00432-007-0320-z 17932690 (Pubitemid 351422610)
17. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. The Lancet Oncology. 2008 9 962 972 10.1016/S1470-2045(08)70206-7 18804418
18. Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. Pallis A, Briasoulis E, Linardou H, et al. Curr Med Chem 2011 18 1613 1628 10.2174/092986711795471383 21428885
19. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E, Histological typing of lung and pleural tumors Springer, Berlin 3 1999
20. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Murray S, Timotheadou E, Linardou H, et al. Lung Cancer 2006 52 225 233 10.1016/j.lungcan.2005.12.015 16567021
21. Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. Murray S, Dahabreh IJ, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P, J Thorac Oncol 2008 3 832 839 10.1097/JTO.0b013e31818071f3 18670300
22. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. Boldrini L, Gisfredi S, Ursino S, et al. J Thorac Oncol 2007 2 1086 1090 10.1097/JTO. 0b013e31815ba1fa 18090579 (Pubitemid 350307900)
23. K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for non homogeneous representation of mutation subtypes. Kislitsin D, Lerner A, Rennert G, Lev Z, Dig Dis Sci 2002 47 1073 1079 10.1023/A:1015090124153 12018902 (Pubitemid 34439183)
24. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Bamias A, Karina M, Papakostas P, et al. Cancer Chemother Pharmacol 2010 65 1009 1021 10.1007/s00280-010-1256-6 20130877
25. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. J Clin Oncol 2003 21 3798 3807 10.1200/JCO.2003.11.069 12953099 (Pubitemid 46606235)
26. MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. Fountzilas G, Kalogera-Fountzila A, et al. J Oncol 2009 2009 305908 20066159
27. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. Hirsch FR, Varella-Garcia M, McCoy J, et al. J Clin Oncol 2005 23 6838 6845 10.1200/JCO.2005.01.2823 15998906
28. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. Cappuzzo F, Marchetti A, Skokan M, et al. J Clin Oncol 2009 27 1667 1674 10.1200/JCO.2008.19.1635 19255323
29. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Zhu CQ, da Cunha Santos G, Ding K, et al. J Clin Oncol 2008 26 4268 4275 10.1200/JCO.2007.14.8924 18626007
30. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Thatcher N, Chang A, Parikh P, et al. Lancet 2005 366 1527 1537 10.1016/S0140-6736(05)67625-8 16257339 (Pubitemid 41540110)
31. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. Douillard JY, Shepherd FA, Hirsh V, et al. J Clin Oncol 2010 28 744 752 10.1200/JCO.2009.24.3030 20038723
32. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. Maemondo M, Inoue A, Kobayashi K, et al. N Engl J Med 2010 362 2380 2388 10.1056/NEJMoa0909530 20573926
33. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Mitsudomi T, Morita S, Yatabe Y, et al. Lancet Oncol 2010 11 121 128 10.1016/S1470-2045(09)70364-X 20022809
34. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Zucali PA, Ruiz MG, Giovannetti E, et al. Ann Oncol 2008 19 1605 1612 10.1093/annonc/mdn240 18467317
35. A molecular cytogenetic analysis of 7q31 in prostate cancer. Jenkins RB, Qian J, Lee HK, et al. Cancer Res 1998 58 759 766 9485032 (Pubitemid 28099489)
36. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. Reinersman JM, Johnson ML, Riely GJ, et al. J Thorac Oncol 2011 6 28 31 10.1097/JTO.0b013e3181fb4fe2 21107288